EMEA-001214-PIP01-11-M08
Key facts
Invented name |
Fasenra
|
Active substance |
benralizumab
|
Therapeutic area |
Pneumology-allergology
|
Decision number |
P/0244/2018
|
PIP number |
EMEA-001214-PIP01-11-M08
|
Pharmaceutical form(s) |
Solution for injection
|
Condition(s) / indication(s) |
Treatment of asthma
|
Route(s) of administration |
Subcutaneous use
|
Contact for public enquiries |
AstraZeneca AB (UK)
E-mail: paediatrics@medimmune.com |
Decision type |
PM: decision on the application for modification of an agreed PIP
|